New insights into mesenchymal stem cells in inflammatory subtypes of asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, heightened reactivity, and structural remodeling. The responses of different phenotypes to traditional corticosteroid therapy vary significantly, with steroid resistance in low T-helper type 2 asthma remaining an urgent...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1649597/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Asthma is a heterogeneous disease characterized by chronic airway inflammation, heightened reactivity, and structural remodeling. The responses of different phenotypes to traditional corticosteroid therapy vary significantly, with steroid resistance in low T-helper type 2 asthma remaining an urgent clinical challenge. In recent years, mesenchymal stem cells (MSCs) and their exosomes—mesenchymal stem cell-derived extracellular vesicles (MSC-EVs)—have emerged as promising therapeutic agents due to their potent immunomodulatory properties. In this review, we systematically explain how MSCs and MSC-EVs inhibit airway inflammation in asthma through multi-target immunoregulation, highlight their therapeutic potential in steroid-resistant asthma, and outline the challenges and optimization strategies involved in clinical translation, thereby providing a theoretical foundation for the development of novel therapies. |
|---|---|
| ISSN: | 1664-3224 |